Prevention

At the Einstein Center for Early Disease Interception, researchers from twelve Berlin institutions will be pooling their expertise to explore new approaches to prevention, long before symptoms appear, and bring them quickly into practice. The center opens today with a ceremony.

The Einstein Center for Early Disease Interception has been funded with six million euros. In an interview, Nikolaus Rajewsky and Leif Erik Sander, both spokespeople of the center, explain why new technologies and cross-institutional collaboration will make disease prevention in the future possible.

The Helmholtz Association has approved €30.8 million in funding for the Center for AI–Accelerated Molecular Innovations in Medicine to be located at the Max Delbrück Center. Researchers will use new technologies to develop AI-driven strategies for precision treatment and prevention.

Where does health end and illness begin – and what happens in between? Researchers working in the ImmunoPreCept Excellence Cluster are planning to take a deep look inside our cells and answer this question. In this interview, the coordinators explain what they hope to achieve in the next seven years.

The Max Delbrück Center is a partner in one newly awarded Berlin based Clusters of Excellence: ImmunoPreCept. NeuroCure has also won another round of funding. All researchers are working toward a common goal – to develop therapies that can intercept diseases on a molecular level.

The Helmholtz Association is pooling its commitment to prevention research with the launch of the Helmholtz Health Prevention Task Force. In a strategy paper published in “Nature Medicine,“ the committee outlines initial concepts for integrating prevention more effectively into medical practice.

In May 2019 the second round of examinations in the German National Cohort (GNC) health study got underway at the MDC. Tobias Pischon, an MDC researcher and a member of the GNC board of directors, explains why additional data are so important to the success of the long-term study.